Edesa Biotech, Inc. Common Shares

Day range

$2.55 – $2.74

Open

$2.70

Prev close

$2.77

Volume

58.54K

Market cap

$26.71M

Shares out

9.64M

P/E

—

P/S

—

P/B

3.03

P/FCF

—

ROE

-160.1%

ROA

-110.9%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Executive compensation changeOct 23, 2026

  On October 23, 2026, the Board of Directors ... approved increases in the annual base salaries of Dr. Pardeep Nijhawan, the Company's Chief Executive Officer, from $357,696 to $657,423, Dr. Michael Brooks, the Company's President, from $335,340 to $591,681, and Peter Weiler, the Company's Chief Financial Officer, from $300,000 to $525,938, in each case pursuant to their respective employment agreements with the Company and retroactive to July 1, 2026.

• Regulatory decisionOct 15, 2026

  “the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigational New Drug ("IND") application for its Phase 2 clinical study of EB06 in vitiligo, enabling the Company to expand recruitment to the United States.”

• Underwriting agreementAug 20, 2026

  On August 19, 2026, Edesa Biotech, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Guggenheim Securities, LLC ("Guggenheim Securities"), as representative of the several underwriters listed in Schedule 1 thereto (the "Underwriters"), in connection with the issuance and sale, in an underwritten, registered offering (the "Offering").

• Clinical trial resultsJun 5, 2026

  On June 5, 2026, Edesa Biotech, Inc. (the "Company") reported favorable exploratory data for paridiprubart, its first-in-class anti-TLR4 monoclonal antibody, in patients with acute kidney injury ("AKI") and respiratory distress. The data, which expand upon previously reported Phase 3 clinical results through new exploratory analyses, will be presented today in a scientific oral presentation at the 63rd European Renal Association ("ERA") Congress in Glasgow, Scotland.

• Equity compensation grantMay 29, 2026

  At the Annual Meeting, shareholders approved an amendment (the 'Plan Amendment') to the Company's 2019 Equity Incentive Compensation Plan (the '2019 Plan') to (i) increase the number of shares available for issuance thereunder by 750,000 shares and (ii) eliminate the annual per participant option grant limit.

Days to cover

4.8

Short interest

203.56K

Avg volume

42.31K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Acute Respiratory Distress Syndrome Market to Grow Steadily at a 3.8% CAGR Through 2036, Supported by Emerging ARDS Therapies | DelveInsight
  positiveGlobeNewswire Inc.· Jun 3, 2026
• Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
  positiveGlobeNewswire Inc.· Aug 14, 2025
• Information Provided Pursuant to Early Warning Requirements with Respect to Par Nijhawan and Velan Capital
  neutralGlobeNewswire Inc.· Feb 13, 2025
• Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.
  neutralGlobeNewswire Inc.· Sep 13, 2024
• Why ReShape Lifesciences Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
  Benzinga· Dec 13, 2023